down arrow

Kaken Pharmaceutical Co., Ltd.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: JP3207000005
JPY
3,910.00
45 (1.16%)

Dec 11

TKS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Comparison
Company
Score
Quality
Valuation
Financial
Technical
Sumitomo Pharma Co., Ltd.
Nippon Shinyaku Co., Ltd.
Tsumura & Co.
Hisamitsu Pharmaceutical Co., Inc.
Santen Pharmaceutical Co., Ltd.
Suzuken Co., Ltd.
JCR Pharmaceuticals Co., Ltd.
Kobayashi Pharmaceutical Co., Ltd.
SAWAI GROUP HOLDINGS Co., Ltd.
Kaken Pharmaceutical Co., Ltd.
Taisho Pharmaceutical Holdings Co., Ltd.
Why is Kaken Pharmaceutical Co., Ltd. ?
1
Poor long term growth as Net Sales has grown by an annual rate of 1.05% and Operating profit at -4.77% over the last 5 years
2
The company has declared negative results in Mar 25 after 2 consecutive negative quarters
  • PRE-TAX PROFIT(Q) At JPY 408 MM has Fallen at -86.29%
  • NET PROFIT(Q) At JPY 270.33 MM has Fallen at -87.72%
  • RAW MATERIAL COST(Y) Grown by 5.09% (YoY)
3
Below par performance in long term as well as near term
  • Along with generating -9.82% returns in the last 1 year, the stock has also underperformed Japan Nikkei 225 in the last 3 years, 1 year and 3 months
stock-recommendationReal-Time Research Report
Verdict Report
How much should you sell?
  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Kaken Pharmaceutical Co., Ltd. for you?

Low Risk, High Return

Absolute
Risk Adjusted
Volatility
Kaken Pharmaceutical Co., Ltd.
-9.82%
994.33
22.12%
Japan Nikkei 225
28.54%
1.11
25.75%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
1.05%
EBIT Growth (5y)
-4.77%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.43
Sales to Capital Employed (avg)
0.54
Tax Ratio
28.25%
Dividend Payout Ratio
52.00%
Pledged Shares
0
Institutional Holding
0.10%
ROCE (avg)
20.37%
ROE (avg)
7.98%
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
12
Industry P/E
Price to Book Value
1.14
EV to EBIT
5.17
EV to EBITDA
4.60
EV to Capital Employed
1.24
EV to Sales
1.14
PEG Ratio
0.15
Dividend Yield
0.03%
ROCE (Latest)
24.03%
ROE (Latest)
9.49%
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Mildly Bullish
Mildly Bullish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
Analyse All Technical Factors stock-recommendation
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

1What is working for the Company
DEBTORS TURNOVER RATIO(HY)

Highest at 4.1%

-28What is not working for the Company
PRE-TAX PROFIT(Q)

At JPY 408 MM has Fallen at -86.29%

NET PROFIT(Q)

At JPY 270.33 MM has Fallen at -87.72%

RAW MATERIAL COST(Y)

Grown by 5.09% (YoY

CASH AND EQV(HY)

Lowest at JPY 125,488 MM

DEBT-EQUITY RATIO (HY)

Highest at -34.96 %

INTEREST(Q)

Highest at JPY 10 MM

Here's what is working for Kaken Pharmaceutical Co., Ltd.
Debtors Turnover Ratio
Highest at 4.1%
in the last five Semi-Annual periods
MOJO Watch
Company has been able to sell its Debtors faster

Debtors Turnover Ratio

Here's what is not working for Kaken Pharmaceutical Co., Ltd.
Pre-Tax Profit
At JPY 408 MM has Fallen at -86.29%
Year on Year (YoY)
MOJO Watch
Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (JPY MM)

Net Profit
At JPY 270.33 MM has Fallen at -87.72%
Year on Year (YoY)
MOJO Watch
Near term Net Profit trend is very negative

Net Profit (JPY MM)

Interest
At JPY 10 MM has Grown at 11.11%
period on period (QoQ)
MOJO Watch
Rising interest cost signifies increased borrowings

Interest Paid (JPY MM)

Interest
Highest at JPY 10 MM
in the last five periods and Increased by 11.11% (QoQ)
MOJO Watch
Rising interest cost signifies increased borrowings

Interest Paid (JPY MM)

Cash and Eqv
Lowest at JPY 125,488 MM
in the last six Semi-Annual periods
MOJO Watch
Short Term liquidity is deteriorating

Cash and Cash Equivalents

Debt-Equity Ratio
Highest at -34.96 %
in the last five Semi-Annual periods
MOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Raw Material Cost
Grown by 5.09% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales

Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."